Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA

PHASE2CompletedINTERVENTIONAL
Enrollment

248

Participants

Timeline

Start Date

August 29, 2022

Primary Completion Date

December 28, 2023

Study Completion Date

January 3, 2024

Conditions
Rheumatoid Arthritis
Interventions
DRUG

MBS2320 5 mg

Oral capsule

DRUG

MBS2320 20 mg

Oral capsule

DRUG

MBS2320 40 mg

Oral capsule

DRUG

Placebo

Oral capsule

Trial Locations (46)

Unknown

Site 1201 - Univerzitetski Klinicki Centar Republike Srpske, Banja Luka

Site 1204 - Univerzitetski Klinicki Centar Republike Srpske, Banja Luka

Site 1202 - General Hospital Gradiška, Gradiška

Site 1308 - Medical Center Medconsult Pleven OOD, Pleven

Site 1302 - Medical Center Artmed OOD, Plovdiv

Site 1303 - Diagnostic and Consulting Center Aleksandrovska EOOD, Sofia

Site 1306 - Diagnostic- Consultative Center Convex EOOD, Sofia

Site 1307 - Medical Center Excelsior OOD - PPDS, Sofia

Site 1301 - University Multiprofile Hospital for Active Treatment - Prof. Dr. Stoyan Kirkovich AD, Stara Zagora

Site 1304 - Medical Center Leo Clinic EOOD, Varna, Varna

Site 2103 - Enroll SpA - PPDS, Providencia

Site 2105 - CTR Estudios, Providencia

Site 2104 - Meditek Ltda, Santiago

Site 2106 - Biocinetic SpA, Santiago

Site 2107 - Hospital Dr Sotero Del Rio, Santiago

Site 2102 - Clinical Research Chile SpA - PPDS, Valdivia

Site 2101 - Oncocentro APYS, Viña del Mar

Site 1104 - CCR Ostrava s.r.o., Ostrava

Site 1101 - CCR Czech, Pardubice

Site 1103 - CLINTRIAL s.r.o., Prague

Site 1102 - MEDICAL PLUS, s.r.o., Uherské Hradište

Site 2401 - Clinica Medica Con Especialidad Reumatologia, Guatemala City

Site 2402 - Clinica Medica Especializada en Reumatologia, Guatemala City

Site 2404 - Reumacentro, Guatemala City

Site 2405 - Hospital Herrera Llerandi, Guatemala City

Site 2406 - Clinica Medica Especializada en Medicina Interna, Guatemala City

Site 2206 - Centro de Alta Especialidad En Reumatologia E Investigacion Del Potosi SC, Burócratas del Estado

Site 2203 - Centro de Estudios de Investigacion Basica Y Clinica SC, Guadalajara

Site 2202 - Morales Vargas Centro de Investigacion SC, León

Site 2201 - Centro de Investigación en Artritis y Osteoporosis - PPDS, Mexicali

Site 2205 - Biológicos Especializados S.A. de C.V., Mexico City

Site 2204 - Centro de Investigación y Tratamiento Reumatológico S.C, Miguel Hidalgo

Site 1006 - ClinicMed Daniluk, Nowak Spółka Jawna, Bialystok

Site 1002 - MICS Centrum Medyczne Bydgoszcz, Bydgoszcz

Site 1009 - Szpital Uniwersytecki Nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz

Site 1007 - NZOZ Lecznica MAK-MED, Nadarzyn

Site 1004 -Twoja Przychodnia NCM, Nowa Sól

Site 1001 - ETYKA Osrodek Badan Klinicznych, Olsztyn

Site 1003 - Centrum Medyczne Reuma Park NZOZ, Warsaw

Site 1008 - Centrum Medyczne AMED, Warsaw

Site 1402 - Institute of Rheumatology Belgrade - PPDS, Belgrade

Site 1403 - Institute of Rheumatology Belgrade - PPDS, Belgrade

Site 1404 - Military Medical Academy, Belgrade

Site 1405 - Institute of Rheumatology Belgrade - PPDS, Belgrade

Site 1406 - Institute for Treatment and Rehabilitation Niska Banja, Niška Banja

Site 1401 - Special Hospital For Rheumatic Diseases Novi Sad, Novi Sad

Sponsors
All Listed Sponsors
lead

Modern Biosciences Ltd

INDUSTRY

NCT05460832 - Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA | Biotech Hunter | Biotech Hunter